Navigation Links
Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment
Date:6/14/2011

NEW BRUNSWICK, N.J., June 14, 2011 /PRNewswire-USNewswire/ -- Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals.  For some, it is just a nuisance. For others, it is disabling.

On a continuing quest to find more effective treatment for psoriasis sufferers, an article published in the Journal of Investigative Dermatology reported that the latest data from experiments performed by Actinobac Biomed, Inc., with financial backing from Foundation Venture Capital Group, LLC, successfully demonstrated the in vivo efficacy of the company's drug candidate, Leukothera™, in treating psoriasis in a humanized mouse xenograft transplantation model.  (http://www.nature.com/jid/journal/vaop/ncurrent/abs/jid2011161a.html)

"Our results clearly show that the idea of depleting diseased white blood cells with Leukothera™ is a highly effective strategy for the treatment of psoriasis and other inflammatory diseases," said Dr. Scott Kachlany, Actinobac's founder.

The studies performed at Aarhus University Hospital in Denmark showed Leukothera™ to be as effective as or better than Genentech's once marketed agent, efalizumab (Raptiva®), even when using significantly lower drug dosage levels.  Leukothera™ is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.  

"We provided early seed funding to Actinobac because we are convinced that they are working on breakthrough research that will make a huge impact to thousands and thousands of people around the world suffering from a variety of ailments," said James M. Golubieski, president of Foundation Venture Capital Group (www.foundationventure.com), an affiliate of New Jersey Health Foundation.  "The publication of Dr. Kachlany's findings relative to the treatment of psoriasis is proof of that."

Actinobac Biomed, Inc. was founded in 2009 to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey.  The company has exclusively licensed the rights to develop Leukothera™ as a therapeutic agent.

The current focus of Actinobac activities involves the development of pharmaceutical technologies based upon the natural biologic agent leukotoxin (Leukothera™), which targets Leukocyte Function Antigen-1 (LFA-1) on diseased white blood cells.  For the work in psoriasis and other autoimmune/inflammatory diseases, Actinobac plans to continue IND-enabling studies to test in humans shortly.

For more information or to explore ways in which to partner with Actinobac, contact them at 732-371-2694, info@actinobac.com, or visit www.actinobac.com.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Prototype demonstrates success of advanced new energy technology
2. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
3. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
4. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
5. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
6. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
7. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
8. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
9. Capasso lab demonstrates highly unidirectional whispering gallery microlasers
10. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
11. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
(Date:6/22/2016)... 22, 2016  According to Kalorama Information, the ... (NGS) market include significant efforts in automation as ... accessible and affordable sequencers, say the healthcare market ... consumables including sample prep materials.  The healthcare market ... Preparation for Next Generation Sequencing (NGS) , highlights ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):